TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 818, Issue , 2017, Pages 17-26

  Aydin, Selda ^a   Ambroise, Jérôme ^a   Cosyns, Jean Pierre ^a   Gala, Jean Luc ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Aristolochic acid; Carcinogenesis; TP53; Urothelial carcinoma

Indexed keywords

ARISTOLOCHIC ACID; DNA; PROTEIN P53; ARISTOLOCHIC ACID I;

ANTIBODY COMBINING SITE; ARTICLE; BELGIAN; CARCINOGENESIS; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; MOLECULAR PATHOLOGY; NEPHROTOXICITY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; ADULT; BELGIUM; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; GENETICS; INTERSTITIAL NEPHRITIS; LASER CAPTURE MICRODISSECTION; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; URINARY TRACT TUMOR; UROTHELIUM;

ADULT; ARISTOLOCHIC ACIDS; BELGIUM; CARCINOGENESIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MIDDLE AGED; MUTATION; NEPHRITIS, INTERSTITIAL; TUMOR SUPPRESSOR PROTEIN P53; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 85017433522     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2017.03.003     Document Type: Article

References (44)

1. [1] Cosyns, J.P., Jadoul, M., Squifflet, J.P., Wese, F.X., van Ypersele de Strihou, C., Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 33 (1999), 1011–1017 (PMID: 10352187).
2. [2] Nortier, J.L., Martinez, M.C., Schmeiser, H.H., Arlt, V.M., Bieler, C.A., Petein, M., Depierreux, M.F., De Pauw, L., Abramowicz, D., Vereerstraeten, P., Vanherweghem, J.L., Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia Fangchi). N. Engl. J. Med. 342 (2000), 1686–1692 (PMID: 10841870).
3. [3] Cosyns, J.P., Aristolochic acid and ‘Chinese herbs nephropathy’: a review of the evidence to date. Drug Saf. 26 (2003), 33–48 (PMID: 12495362).
4. [4] Grollman, A.P., Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ. Mol. Mutagen. 54 (2013), 1–7 (PMID: 23238808).
5. [5] Vanherweghem, J.L., Depierreux, M., Tielemans, C., Abramowicz, D., Dratwa, M., Jadoul, M., Richard, C., Vandervelde, D., Verbeelen, D., Vanhaelen-Fastre, R., et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341 (1993), 387–391 (PMID: 8094166).
6. [6] Vanhaelen, M., Vanhaelen-Fastre, R., But, P., Vanherweghem, J.L., Identification of aristolochic acid in Chinese herbs. Lancet, 343, 1994, 174 (PMID: 7904018).
7. [7] Aydin, S., Dekairelle, A.F., Ambroise, J., Durant, J.F., Heusterspreute, M., Guiot, Y., Cosyns, J.P., Gala, J.L., Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection. PLoS One, 9, 2014, e106301 (PMID: 25184754]).
8. [8] Grollman, A.P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., Fernandes, A., Rosenquist, T., Medverec, Z., Jakoniva, K., Brdar, B., Slade, N., Turesky, R.J., Goodenough, A.K., Rieger, R., Vukelic, M., Jelakovic, B., Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 12129–12134 (PMID: 17620607).
9. [9] Moriya, M., Slade, N., Brdar, B., Medverec, Z., Tomic, K., Jelakovic, B., Wu, L., Truong, S., Fernandes, A., Grollman, A.P., TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int. J. Cancer 129 (2011), 1532–1536 (PMID: 21413016).
10. [10] Chen, C.H., Dickman, K.G., Moriya, M., Zavadil, J., Sidorenko, V.S., Edwards, K.L., Gnatenko, D.V., Wu, L., Turesky, R.J., Wu, X.R., Pu, Y.S., Grollman, A.P., Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 8241–8246 (PMID: 22493262).
11. [11] Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P., Olivier, M., Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28 (2007), 622–629 (Available: http://www-p53.iarc.fr/).
12. [12] Chen, C.H., Dickman, K.G., Huang, C.Y., Moriya, M., Shun, C.T., Tai, H.C., Huang, K.H., Wang, S.M., Lee, Y.J., Grollman, A.P., Pu, Y.S., Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int. J. Cancer 133 (2013), 14–21 (PMID: 23292929).
13. [13] Cosyns, J.P., Goebbels, R.M., Liberton, V., Schmeiser, H.H., Bieler, C.A., Bernard, A.M., Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no onterstitial nephropathy in rats. Arch. Toxicol. 72 (1998), 738–743 (PMID: 9879812).
14. [14] Hranjec, T., Kovac, A., Kos, J., Mao, W., Chen, J.J., Grollman, A.P., Jelakovic, B., Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat. Med. J. 46 (2005), 116–125 (PMID: 15726685).
15. [15] Yang, L., Su, T., Li, X.M., Wang, X., Cai, S.Q., Meng, L.Q., Zou, W.Z., Wang, H.Y., Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol. Dial. Transplant. 27 (2012), 292–298 (PMID: 21719716).
16. [16] Eble, J.N., Sauter, G., Epstein, J.I., Sesterhenn, I.A., (eds.) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, 2004, IARC Press, Lyon, France.
17. [17] Nedelko, T., Arlt, V.M., Phillips, D.H., Hollstein, M., TP53 mutation signature supports involvement of arisrolochic acid in the aetiology of endemic nephropathy-associated tumours. Int. J. Cancer 124 (2009), 987–990 (PMID: 19030178).
18. [18] Liu, Z., Hergenhahn, M., Schmeiser, H.H., Wogan, G.N., Hong, A., Hollstein, M., Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harbouring a humanized p53 gene. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 2963–2968 (PMID: 14976251).
19. [19] Nanda, M.S., Shah, Z.A., Sameer, A.S., Syeed, N., Murtaza, I., Siddiqi, M.A., Ali, A., TP53-molecular soldier's mutations in bladder cancer in the Kashmiri population. Asian Pac. J. Cancer Prev. 12 (2011), 67–72 (PMID: 21517233).
20. [20] Arlt, V.M., Wiessler, M., Schmeiser, H.H., Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene. Carcinogenesis 21 (2000), 235–242 (PMID: 10657963).
21. [21] Arlt, V.M., Schmeiser, H.H., Pfeifer, G.P., Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22 (2001), 133–140 (PMID: 11159751).
22. 32P-post-labelling analysis of DNA adducts formed by aristolochis acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18 (1997), 1063–1067 (PMID: 9163697).
23. [23] Fernando, R.C., Schmeiser, H.H., Scherf, H.R., Wiessler, M., Formation and persistence of specific purine adducts by 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I. IARC Sci. Publ. 124 (1993), 167–171 (PMID: 8225480).
24. [24] Broschard, T.H., Wiessler, M., von der Lieth, C.W., Schmeiser, H.H., Translesional synthesis on DNA templates containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. Carcinogenesis 15 (1994), 2331–2340 (PMID: 7955074).
25. [25] Arlt, V.M., Stiborova, M., Schmeiser, H.H., Aristolochic acid a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17 (2002), 265–277 (PMID: 12110620).
26. [26] Attaluri, S., Bonala, R.R., Yang, I.Y., Lukin, M.A., Wen, Y., Grollman, A.P., Moriya, M., Iden, C.R., Johnson, F., DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res. 38 (2010), 339–352 (PMID: 19854934).
27. [27] Leung, E.M., Chan, W., Comparison of DNA and RNA adduct formation: significantly higher levels of RNA than DNA modifications in the internal organs of Aristolochic acid-dosed rats. Chem. Res. Toxicol. 28 (2015), 248–255 (PMID: 25555167).
28. [28] Hollstein, M., Moriya, M., Grollman, A.P., Olivier, M., Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, arictolochic acid. Mutat. Res. 753 (2013), 41–49 (PMID: 23422071).
29. [29] Wang, Y., Meng, F., Arlt, V.M., Mei, N., Chen, T., Parsons, B.L., Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction. Mutagenesis 26 (2011), 619–628 (PMID: 21642617).
30. [30] Nenutil, R., Smardova, J., Pavlova, S., Hanzelkova, Z., Muller, P., Fabian, P., Hrstka r Janotova, P., Radina, M., Lane, D.P., Coates, P.J., Vojtesek, B., Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J. Pathol. 207 (2005), 251–259 (PMID: 16161005).
31. [31] López, I., Oliveira, P.L., Tucci, P., Alvarez-Valin, F., Coudry, R., Marin, M., Different mutation profiles associated to P53 accumulation in colorectal cancer. Gene. 499 (2012), 81–87 (PMID: 22373952).
32. [32] Colomer, A., Erill, N., Verdú, M., Román, R., Vidal, A., Cordon-Cardo, C., Puig, X., Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas. Appl. Immunohistochem. Mol. Morphol. 11 (2003), 130–137 (PMID: 12777996).
33. [33] Peltonen, J.K., Helppi, H.M., Pääkkö, P., Turpeenniemi-Hujanen, T., Vähäkangas, K.H., P53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations. Head Neck Oncol., 2, 2010, 36 (PMID: 21159183).
34. [34] Brosh, R., Rotter, V., When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9 (2009), 701–713 (PMID: 19693097).
35. [35] Weisz, L., Oren, M., Rotter, V., Transcription regulation by mutant p53. Oncogene 26 (2007), 2202–2211 (PMID: 17401429).
36. [36] Casson, A.G., Wilson, S.M., McCart, J.A., O'Malley, F.P., Ozcelik, H., Tsao, M.S., Chambers, A.F., Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int. J. Cancer 72 (1997), 739–745 (PMID: 9311587).
37. [37] Holstege, H., Joosse, S.A., van Oostrom, C.T., Nederlof, P.M., de Vries, A., Jonkers, J., High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 69 (2009), 3625–3633 (PMID: 19336573).
38. [38] Takami, H., Yoshida, A., Fukushima, S., Arita, H., Matsushita, Y., Nakamura, T., Ohno, M., Miyakita, Y., Shibui, S., Narita, Y., Ichimura, K., Revisiting TP53 mutations and immunohistochemistry-a comparative study in 157 diffuse gliomas. Brain Pathol. 25 (2015), 256–265 (PMID: 25040820).
39. [39] Watanabe, J., Nishiyama, H., Okubo, K., Takahashi, T., Toda, Y., Habuchi, T., Kakehi, Y., Tada, M., Ogawa, O., Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology 63 (2004), 989–993 (PMID: 15135005).
40. [40] Gao, J.P., Uchida, T., Wang, C., Jiang, S.X., Matsumoto, K., Satoh, T., Minei, S., Soh, S., Kameya, T., Baba, S., Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int. J. Oncol. 16 (2000), 469–475 (PMID: 10675477).
41. [41] Cheng, L., Zhang, S., MacLennan, G.T., Williamson, S.R., Lopez-Beltran, A., Montironi, R., Bladder cancer: translating molecular genetic insights into clinical practice. Hum. Pathol. 42 (2011), 455–481 (PMID: 21106220).
42. [42] Hodges, K.B., Lopez-Beltran, A., Davidson, D.D., Montirino, R., Cheng, L., Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum. Pathol. 41 (2010), 155–162 (PMID: 19762067).
43. [43] Arlt, V.M., Pfohl-Leszkowicz, A., Cosyns, J., Schmeiser, H.H., Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. Mutat. Res. 494 (2001), 143–150 (PMID: 11423353).
44. [44] Kanaan, N., Hassoun, Z., Raggi, C., Jadoul, M., Mourad, M., De Meyer, M., Aydin, S., Schmeiser, H.H., Cosyns, J.P., Goffin, E., Long-term outcome of kidney recipients transplanted for aristolochic acid nephropathy. Transplantation 100 (2016), 416–421 (PMID: 26457602).